Delving into the Latest Updates on Roxadustat with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

ROX-MAE@LP, Roxadustat (JAN/USAN/INN), 可博美

+ [11]

Target

HIF-PHs

Action

inhibitors

Mechanism

HIF-PHs inhibitors(Hypoxia-inducible factor prolyl hydroxylase inhibitors)

Therapeutic Areas

Hemic and Lymphatic DiseasesUrogenital DiseasesEndocrinology and Metabolic Disease+ [2]

Active Indication

AnemiaAnemia in chronic kidney diseaseAnemia of renal disease+ [4]

Inactive Indication

Myelodysplastic SyndromesNeoplasmsPeritoneal Diseases

Originator Organization

FibroGen, Inc.

Active Organization

FibroGen (China) Medical Technology Development Co. Ltd.Astellas Pharma Global Development, Inc.

Zhejiang Jianfeng Pharmaceutical Co., Ltd.

+ [5]

Inactive Organization

FibroGen, Inc.

AstraZeneca Canada, Inc.

License Organization

FibroGen (China) Medical Technology Development Co. Ltd.

AstraZeneca PLC

Astellas Pharma, Inc.

+ [2]

Drug Highest PhaseApproved

First Approval Date

China (17 Dec 2018),

chronic renal failure anemia

RegulationPriority Review (China), Special Review Project (China)

Login to view timeline

Structure/Sequence

Molecular FormulaC19H16N2O5

InChIKeyYOZBGTLTNGAVFU-UHFFFAOYSA-N

CAS Registry808118-40-3

Sarcopenia, abbreviated as muscle loss, is a prevalent complication among patients with chronic kidney disease (CKD), particularly those with end - stage renal disease (ESRD). It significantly impacts patients' quality of life. The prevalence of sarcopenia in patients receiving maintenance hemodialysis (MHD) ranges from 32.7% to 73.5%, which is substantially higher than that in the general population (5% - 13%). Sarcopenia significantly elevates the mortality risk in MHD patients. Specifically, sarcopenia patients experience an increased all - cause mortality rate, a heightened risk of cardiovascular events, a decline in quality of life, and an augmented risk of falls and fractures. A close pathophysiological relationship exists between the hypoxia - inducible factor - 1 (HIF - 1) pathway and sarcopenia. HIF - 1α serves as a key transcription factor for cells to respond to hypoxic conditions. Under normoxic conditions, HIF - 1α is hydroxylated by prolyl hydroxylase (PHD) and subsequently undergoes ubiquitination - mediated degradation. Conversely, under hypoxic circumstances, HIF - 1α is stably expressed, translocates into the nucleus, and activates downstream target genes. HIF - 1α promotes the expression of genes associated with glycolysis, such as GLUT1 and LDHA, while inhibiting mitochondrial oxidative phosphorylation. This results in a shift of skeletal muscle energy metabolism from aerobic to anaerobic pathways. Research has revealed that the protein level of HIF - 1α is significantly decreased in sarcopenia patients. Roxadustat capsules, an oral medication, represent the world's first small - molecule hypoxia - inducible factor prolyl hydroxylase inhibitor (HIF - PHI) developed for the treatment of renal anemia. The physiological function of HIF - 1α not only enhances the expression of erythropoietin but also upregulates the expression of erythropoietin receptors and proteins involved in promoting iron absorption and circulation. Theoretically, roxadustat has the potential to improve sarcopenia. However, due to its prominent effect on anemia correction, it is currently only clinically applicable to anemic patients. This study aims to use ESA as a control to investigate the effect of roxadustat on sarcopenia in hemodialysis patients during the treatment of renal anemia.

Start Date10 Sep 2025

Sponsor / Collaborator

Tianjin Medical University General Hospital

ACTRN12625000491460

/ Not yet recruitingPhase 2IIT

An open-label volunteer study of the impact of short-term oral Roxadustat exposure on gene expression in whole blood in healthy adults aged 40 years and over.

Start Date16 Jun 2025

Sponsor / Collaborator

Royal Perth Hospital

CTR20252221

/ CompletedNot Applicable

罗沙司他胶囊人体生物等效性试验

[Translation] Bioequivalence study of roxadustat capsules in humans

以中国健康研究参与者为试验对象，采用自身交叉对照的试验设计，测定江苏德源药业股份有限公司研制生产的罗沙司他胶囊[规格：50 mg]给药后罗沙司他在健康研究参与者体内的血药浓度经时过程，估算相应的药代动力学参数，并以珐博进（中国）医药技术开发有限公司持证生产的罗沙司他胶囊（商品名：爱瑞卓®）为参比制剂，考察受试制剂的相对生物利用度，评价制剂间的生物等效性，并观察受试制剂和参比制剂在中国健康研究参与者中的安全性。

[Translation]

Methods: Participants of the Chinese Health Study were used as the test subjects. A self-crossover design was used to determine the time course of roxadustat plasma concentrations in the healthy study participants after administration of roxadustat capsules [specification: 50 mg] developed and produced by Jiangsu Deyuan Pharmaceutical Co., Ltd., and the corresponding pharmacokinetic parameters were estimated. Roxadustat capsules (trade name: Aeridro®) produced with a license by FibroGen (China) Pharmaceutical Technology Development Co., Ltd. were used as the reference preparation to investigate the relative bioavailability of the test preparation, evaluate the bioequivalence between the preparations, and observe the safety of the test preparation and the reference preparation in the Chinese Health Study participants.

Start Date03 Jun 2025

Sponsor / Collaborator

Jiangsu Deyuan Pharmaceutical Co., Ltd.

100 Clinical Results associated with Roxadustat

Login to view more data

100 Translational Medicine associated with Roxadustat

Login to view more data

100 Patents (Medical) associated with Roxadustat

Login to view more data

622

Literatures (Medical) associated with Roxadustat

31 Dec 2025·RENAL FAILURE

Effect of roxadustat on lowering blood lipids in peritoneal dialysis patients with anemia

Article

Author: Zang, Xiujuan ; Huang, Xiaomin ; Ma, Yuhua ; Zhang, Chunyan ; Ruan, Yilin ; Chen, Nan ; Wang, Yi ; Yu, Geping ; Xu, Tian ; Xie, Jingyuan ; Ren, Hong ; Qi, Hualin ; Mi, Xiuhua ; Liu, Na

OBJECTIVES:

To observe the effect of roxadustat on lowering blood lipids in peritoneal dialysis (PD) patients beyond treating anemia.

METHODS:

In a prospective, multicenter clinical study, we randomly assigned (in a 1:1 ratio) 100 PD patients who had received erythropoiesis-stimulating agent therapy for at least 4 weeks to receive either roxadustat or erythropoietin (EPO) for 48 weeks. The blood lipids, hemoglobin, blood pressure, blood glucose, iron metabolism and inflammatory factors were compared between the two groups at 0, 2, 4, 8, 12, 16, 20, 24 and 48 weeks, respectively.

RESULTS:

At start of switching to roxadustat, hemoglobin seemed to rise a little faster (102.8 ± 15.4 vs. 97.1 ± 17.3 g/L at 2 weeks, p > 0.05), but there was no significant difference in hemoglobin change between the two groups over the course of observation (p = 0.185). At the early stage of the study (12 weeks), the transferrin saturation (TSAT) of roxadustat group decreased significantly from the baseline (32.7 (20.6) vs. 22.1 (18.7)%, p = 0.001). At the end of the study period (48 weeks), total cholesterol (3.89 ± 0.92 vs. 4.52 ± 1.14 mmol/L, p = 0.012), low density lipoprotein cholesterol (2.24 ± 0.74 vs. 2.63 ± 0.82 mmol/L, p = 0.045) and triglyceride (1.35 (0.86) vs. 1.89 (1.27) mmol/l, p = 0.013) in roxadustat group were significantly lower than those in EPO group.

CONCLUSIONS:

Roxadustat not only can improve anemia and iron metabolism, but also can reduce serum cholesterol and triglyceride levels in PD patients after switching from the EPO.

31 Dec 2025·RENAL FAILURE

Analysis of red blood cell lifespan and associated influencing factors in anemic dialysis patients

Article

Author: Zuo, Li ; Shao, Yanyan ; Wang, Chunfang ; Zhu, Li ; Wu, Bei ; Zhao, Huiping ; Bai, Li ; Wang, Yan ; Zhao, Xinju ; Gan, Liangying ; Feng, Ji ; Wu, Jiaqing ; Gao, Weili ; Lu, Lixia

INTRODUCTION:

Renal anemia is one of the most common complications in dialysis patients. The shortened red blood cell (RBC) lifespan is an important mechanism of renal anemia. This study aims to investigate the RBC lifespan and its influencing factors in anemic dialysis patients.

METHOD:

Prevalent patients on maintenance hemodialysis or peritoneal dialysis, treated with anti-anemia therapy including recombinant human erythropoietin (rHuEPO) or roxadustat for more than 4 months were enrolled. RBC lifespan was measured by the RBC lifespan analyzer RBCS-01A depended on Levitt's carbon monoxide (CO) breath test. Participants were primarily divided into low and high RBC lifespan groups by the average value.

RESULT:

A total of 187 patients were included in this study. The average RBC lifespan was 65.2 ± 28.55 days. The logistic regression analysis indicated treating with roxadustat rather than rHuEPO [OR 2.94, 95% CI (1.46, 5.95), p < 0.01], male [OR 2.15, 95% CI (1.08, 4.29), p = 0.03], higher body mass index (BMI) [OR 1.17, 95% CI (1.07, 1.27), p < 0.01], and higher total iron-binding capacity (TIBC) [OR 1.04, 95% CI (1.01, 1.06), p = 0.01] were independent risk factors for the shorten of RBC lifespan. While higher adjusted calcium [OR 0.14, 95% CI (0.03, 0.70), p = 0.02] and older age [OR 0.96, 95% CI (0.94, 0.99), p = 0.01] were independent protective factors.

CONCLUSION:

This study demonstrated that independent risk factors contributing to this reduction in RBC lifespan include male, elevated BMI, increased TIBC, and decreased adjusted calcium levels. Additionally, the type of anti-anemia therapy administered appears to have an impact on RBC lifespan.

01 Nov 2025·EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Recent advance of hypoxia-inducible factor prolyl hydroxylases inhibitors for anemia therapy

Review

Author: Yao, Shenshen ; Wang, Yang ; Wang, Dan ; Feng, Chong ; Zhao, Wancheng ; Ni, Sha

Recent advancements in prolyl hydroxylase domain enzyme (PHD) inhibitors have revolutionized anemia treatment by targeting hypoxia-inducible factor (HIF) pathways. Initially, PHD enzymes were identified as critical regulators of HIF-α degradation under normoxia. The discovery of PHD inhibitors emerged from understanding their role in stabilizing HIF-α, which stimulates erythropoietin (EPO) production and iron metabolism, addressing anemia pathophysiology. Early inhibitors, such as FG-2216, demonstrated proof-of-concept but faced safety concerns, prompting structural optimization to enhance selectivity and pharmacokinetic profiles. Subsequent generations, exemplified by roxadustat, incorporated modifications to reduce off-target effects and improve oral bioavailability, achieving clinical efficacy in renal anemia. Optimization strategies focused on balancing potency, tissue specificity, and minimizing adverse effects. The iterative discovery-to-optimization process underscores the value of PHD inhibitors as templates for novel therapies targeting hypoxia-responsive diseases, while ongoing research addresses challenges in long-term safety and patient-specific response variability. This progress solidifies PHD inhibitors as pivotal tools for anemia management and broader therapeutic innovation.

190

News (Medical) associated with Roxadustat

02 Sep 2025

·fibrogen.gcs-web.com

FibroGen Completes Sale of FibroGen China to AstraZeneca for Approximately $220 Million

Total consideration for the sale of FibroGen China to AstraZeneca is approximately $220 million, a $60 million increase from initial guidance Successfully repaid term loan to Morgan Stanley Tactical Value, further simplifying the Company’s capital structure Phase 2 monotherapy trial of FG-3246 in metastatic castration-resistant prostate cancer (mCRPC) remains on track to begin in 3Q 2025 Cash runway extended into 2028 SAN FRANCISCO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced it has completed the sale of its China subsidiary to AstraZeneca for a total consideration of approximately $220 million, consisting of $85 million in enterprise value and approximately $135 million in net cash held in China. “We are thrilled to announce the completion of the sale of FibroGen China to AstraZeneca and are thankful to the teams who worked relentlessly to bring this to a successful close. This transformative transaction substantially strengthens our financial position, and extends our cash runway into 2028, through important clinical milestones,” said Thane Wettig, Chief Executive Officer of FibroGen. “With a rejuvenated capital structure, we are on track to commence the Phase 2 monotherapy trial of FG-3246 in mCRPC imminently as well as submit the Phase 3 protocol for roxadustat in anemia associated with lower-risk MDS in the fourth quarter of 2025. Additionally, I would like to express my personal gratitude to our FibroGen China colleagues for their unwavering commitment to the success of roxadustat and to AstraZeneca for being an excellent partner over the past 10 years in China.” The completion of the sale follows the fulfilment of all closing conditions. At closing, FibroGen repaid its term loan facility to investment funds managed by Morgan Stanley Tactical Value for approximately $81 million. The successful completion of the sale extends the Company’s cash runway into 2028. FibroGen maintains its rights to roxadustat in the U.S. and in all markets not licensed to Astellas (other than China and South Korea). Following a positive meeting with the U.S. Food and Drug Administration (FDA), the Company intends to file the pivotal Phase 3 clinical trial protocol for roxadustat for the treatment of anemia in patients with LR-MDS and high transfusion burden in the fourth quarter of 2025. In addition, FibroGen continues to advance the clinical development of its lead asset FG-3246, and its companion diagnostic FG-3180, and is on track to initiate the Phase 2 monotherapy trial of FG-3246 in patients with mCRPC in the third quarter of 2025. BofA Securities, Inc. acted as exclusive financial advisor and Ropes & Gray LLP acted as primary legal advisor to FibroGen on this transaction. About FibroGen FibroGen, Inc. is a biopharmaceutical company focused on development of novel therapies at the frontiers of cancer biology and anemia. Roxadustat (爱瑞卓®, EVRENZOTM) is currently approved in China, Europe, Japan, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis. The Company continues to evaluate a development plan for roxadustat in anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) in the U.S. FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46 is in development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of FG-3180, an associated CD46-targeted PET biomarker. For more information, please visit www.fibrogen.com. Forward-Looking Statements This release contains forward-looking statements regarding FibroGen’s strategy, future plans and prospects, including statements regarding its commercial products and clinical programs. These forward-looking statements include, but are not limited to, statements regarding regulatory interactions, the closing of the sale of FibroGen China and the approximate proceeds and costs therefrom, statements regarding the expectation that cash, cash equivalents and accounts receivable will be sufficient to fund FibroGen’s operating plans into 2028, and statements about FibroGen’s plans and objectives. These forward-looking statements are typically identified by use of terms such as “may,” “will”, “should,” “on track,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” and similar words, although some forward-looking statements are expressed differently. FibroGen’s actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the continued progress and timing of its various programs, including the enrollment and results from ongoing and potential future clinical trials, and other matters that are described in FibroGen’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, each as filed with the Securities and Exchange Commission (SEC), including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and FibroGen undertakes no obligation to update any forward-looking statement in this press release, except as required by law. For Investor Inquiries: David DeLucia, CFA Senior Vice President and Chief Financial Officer ir@fibrogen.com Source: FibroGen, Inc.

Phase 2Drug ApprovalPhase 3

27 Aug 2025

·fibrogen.gcs-web.com

FibroGen to Present at the H.C. Wainwright 27th Annual Global Investment Conference

SAN FRANCISCO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the Company will be attending and presenting at the H.C. Wainwright 27th Annual Global Investment Conference being held September 8-10, 2025, in New York, NY. Thane Wettig, Chief Executive Officer of FibroGen, will deliver a company presentation on Tuesday, September 9 at 12:00 PM ET at the Lotte New York Palace Hotel. A live webcast of the presentation will be available here. FibroGen’s management team will be available for one-on-one meetings during the conference. Interested investors should contact their representative at H.C. Wainwright. A replay of the presentation will be posted, when available, to the FibroGen website on the Events & Presentation page of the Investors and Media section for 90 days. About FibroGen FibroGen, Inc. is a biopharmaceutical company focused on development of novel therapies at the frontiers of cancer biology and anemia. Roxadustat (爱瑞卓®, EVRENZO™) is currently approved in China, Europe, Japan, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis. The Company continues to evaluate a development plan for roxadustat in anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) in the U.S. FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46 is in development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of FG-3180, an associated CD46-targeted PET biomarker. For more information, please visit www.fibrogen.com. For Investor Inquiries: David DeLucia, CFA Senior Vice President and Chief Financial Officer ir@fibrogen.com Source: FibroGen, Inc.

ADCDrug Approval

18 Aug 2025

·fibrogen.gcs-web.com

FibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation

Sale of FibroGen China remains on track to close in 3Q 2025 SAN FRANCISCO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the China State Administration for Market Regulation approved the sale of FibroGen International (Hong Kong) Ltd. to AstraZeneca Treasury Limited, pursuant to the Share Purchase Agreement, dated February 20, 2025. The closing of the transaction remains subject to other contractual closing conditions and deliverables and remains on track to close in the third quarter of 2025. About FibroGen FibroGen, Inc. is a biopharmaceutical company focused on development of novel therapies at the frontiers of cancer biology and anemia. Roxadustat (爱瑞卓®, EVRENZO™) is currently approved in China, Europe, Japan, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis. The Company continues to evaluate a development plan for roxadustat in anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) in the U.S. FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46 is in development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of FG-3180, an associated CD46-targeted PET biomarker. For more information, please visit www.fibrogen.com. Forward-Looking Statements This release contains forward-looking statements regarding FibroGen’s strategy, future plans and prospects, including statements regarding its commercial products and clinical programs. These forward-looking statements include, but are not limited to, statements regarding regulatory interactions, the closing of the sale of FibroGen China, and statements about FibroGen’s plans and objectives. These forward-looking statements are typically identified by use of terms such as “may,” “will”, “should,” “on track,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” and similar words, although some forward-looking statements are expressed differently. FibroGen’s actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the continued progress and timing of its various programs, including the enrollment and results from ongoing and potential future clinical trials, and other matters that are described in FibroGen’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, each as filed with the Securities and Exchange Commission (SEC), including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and FibroGen undertakes no obligation to update any forward-looking statement in this press release, except as required by law. For Investor Inquiries: David DeLucia, CFA Senior Vice President and Chief Financial Officer ir@fibrogen.com Source: FibroGen, Inc.

Drug ApprovalADC

100 Deals associated with Roxadustat

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D10593	Roxadustat	B03XA05	DB04847

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Anemia	United Kingdom	Astellas Pharma, Inc.	01 Dec 2021
Anemia in chronic kidney disease	South Korea	AstraZeneca PLC	09 Jul 2021
Anemia of renal disease	Japan	Astellas Pharma, Inc.	20 Sep 2019
chronic renal failure anemia	China	FibroGen (China) Medical Technology Development Co. Ltd.	17 Dec 2018

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Neoplasms	Phase 3	China	FibroGen, Inc.	16 Mar 2022
Myelodysplastic Syndromes	Phase 3	United States	Astellas Pharma, Inc.	29 Jan 2018
Myelodysplastic Syndromes	Phase 3	United States	AstraZeneca PLC	29 Jan 2018
Myelodysplastic Syndromes	Phase 3	United States	FibroGen, Inc.	29 Jan 2018
Myelodysplastic Syndromes	Phase 3	Australia	AstraZeneca PLC	29 Jan 2018
Myelodysplastic Syndromes	Phase 3	Australia	FibroGen, Inc.	29 Jan 2018
Myelodysplastic Syndromes	Phase 3	Australia	Astellas Pharma, Inc.	29 Jan 2018
Myelodysplastic Syndromes	Phase 3	Belgium	Astellas Pharma, Inc.	29 Jan 2018
Myelodysplastic Syndromes	Phase 3	Belgium	AstraZeneca PLC	29 Jan 2018
Myelodysplastic Syndromes	Phase 3	Belgium	FibroGen, Inc.	29 Jan 2018

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04408820 (Pubmed \| Expert Opin Pharmacother)	Not Applicable	Anemia in chronic kidney disease C-reactive protein \| albumin	2,084	roxadustat (Non-dialysis-dependent group)	fvoaadwgom(blyezcfujx) = hlznnflpec hwvbruuqmg (nocrcobjhv ) View more	Positive	04 Mar 2025
				roxadustat (Hemodialysis group)	fvoaadwgom(blyezcfujx) = mmaqeivdjj hwvbruuqmg (nocrcobjhv ) View more
NCT05301517 (Pubmed \| J Clin Oncol)	Phase 3	Anemia	159	Roxadustat	rixwrogrec(qbkwybuprk) = rboicnfocy gmozmqqrdl (rdoaxatejh, 13.58 - 20.71)	Positive	10 Jan 2025
				Recombinant human erythropoietin-α (rHuEPO-α)	rixwrogrec(qbkwybuprk) = nwtwjhokxm gmozmqqrdl (rdoaxatejh, 11.34 - 19.50)
NCT03263091 (MATTERHORN, CTgov)	Phase 3	Anemia \| Myelodysplastic Syndromes	184	Roxadustat (OL Component (Cohort 1): Roxadustat 1.5 mg/kg)	cibhemynmw = otkpkzxlol ppczvgyxtj (bcjugwskhx, qaqhsexejj - qcsfxbzbfd) View more	-	01 Aug 2024
				Roxadustat (OL Component (Cohort 2): Roxadustat 2.0 mg/kg)	cibhemynmw = sefielgmes ppczvgyxtj (bcjugwskhx, kshtoqhwfk - rvbfxefxrn) View more
NCT04655027 (CTgov)	Phase 4	Anemia in chronic kidney disease	25	Roxadustat (Roxadustat)	lqrukfaias(xsvfpfsxsf) = dequhcrdrs jwikvgtown (cmapldsspl, 28.1506) View more	-	22 Apr 2024
				rHuEPO (rHuEPO)	lqrukfaias(xsvfpfsxsf) = wkgslrlrjy jwikvgtown (cmapldsspl, 9.7369) View more
NCT02052310 \| NCT02174731 \| NCT02278341 \| NCT02273726 (Pubmed)	Phase 3	Chronic Kidney Diseases hemoglobin level \| transferrin saturation	2,354	Roxadustat	rxrkexrurn(skpneoktnm) = high hemoglobin rate of rise (≥ 0.5 g/dL/week; odds ratio [OR] 2.09; 95% confidence interval [CI] 0.98-4.46) showed a trend towards increased risk of thromboembolic events before week 12 omfohrlddb (kzollqxwxu ) View more	-	01 Apr 2024
NCT02780141 \| NCT02952092 \| NCT02779764 \| NCT02780726 (Pubmed \| Adv Ther)	Phase 3	Chronic Kidney Diseases transferrin saturation \| transferrin level \| roxadustat dose ... View more	444	Roxadustat	qybjqrybgb(jsckpmkcty) = bcvtuukmxg glsyitmmuq (mwikucdbkk )	Negative	01 Apr 2024
NCT03263091 (MATTERHORN, GlobeNewswire) Manual	Phase 3	Myelodysplastic Syndromes	62	Roxadustat (higher transfusion burden)	jbrjprudsz(xartwfdwnq) = woclizxfaz fvarhlgumy (bhpcoluhra, 20.8 - 53.8) View more	Positive	09 Dec 2023
				placebo (higher transfusion burden)	jbrjprudsz(xartwfdwnq) = opptszitqv fvarhlgumy (bhpcoluhra, 2.4 - 30.2) View more
NCT03263091 (MATTERHORN, ASH2023)	Phase 3	Myelodysplastic Syndromes	140	Roxadustat	mpkdsndqnt(ovjbuvitau) = percentages of pts with TEAEs leading to treatment discontinuation were similar across arms uwgwzjxwty (ppqwkqvjar ) View more	Positive	09 Dec 2023
				Placebo
FGCL-4592-898 (ESMO 12023 \| ESMO 22023) Manual	Phase 3	Neoplasms	140	Roxadustat	wnxjzrcbaf(osqpiexedd) = pdmsvgggmo ovghhofjbp (sqlnwtloqs, 13.58 - 20.71)	Non-inferior	21 Oct 2023
				rHuEPO-α	wnxjzrcbaf(osqpiexedd) = fiqinvgzhs ovghhofjbp (sqlnwtloqs, 11.34 - 19.50)
NCT02052310 \| NCT02174731 \| NCT02278341 \| NCT02273726 (#2959, ERA2023)	Phase 3	Anemia \| Inflammation \| Chronic Kidney Diseases	4,072	Roxadustat	sxfwjupkfz(eecngqface) = The overall percentages of patients with at least one treatment-emergent adverse event were similar for patients treated with roxadustat or ESA across hsCRP quintiles. amwxzdgyan (vvtvhqrpgl )	Positive	14 Jun 2023